Palvella Therapeutics, Inc.
PVLA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.53B
Close$
$5.10
97.1% downside
Current Fair Value
97.1% downsideOvervalued by 97.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.53 Billion |
|---|---|
| Enterprise Value | $2.34 Billion |
| Earnings per Share | $-3.71 |
| Beta | -0.17 |
| Outstanding Shares | 14,531,595 |
Return
| Return on Equity | -37.89% |
|---|---|
| Return on Assets | -31.33% |
| Return on Invested Capital | -24.22% |
Valuation & Multiples
| P/E Ratio | -31.99 |
|---|---|
| PEG | -27.29 |
| Price to Sales | - |
| Price to Book Ratio | 13.53 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -43.08 |
| Enterprise Value to Net Income | -32 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS Estimate
$-1.78
Consensus analyst estimateRevenue Estimate
$16,667
Consensus analyst estimateNext Earnings Call
Expected Date
March 30, 2027
EPS Estimate
$-1.81
Consensus analyst estimateRevenue Estimate
$16,667
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 93.62% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.33%▼ 107.61% |
|---|---|
| Total Invested | $6.47M▼ 99.70% |
| Investors Holding | 15▼ 193.00% |
About Palvella Therapeutics, Inc.
14 employees
CEO: Mr. Wesley H. Kaupinen
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamy...